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Abstract 
Purpose Metastatic oesophageal cancer is commonly considered as a palliative situation with a poor prognosis. However, 
there is increasing evidence that well-selected patients with a limited number of liver metastases (ECLM) may benefit from 
a multimodal approach including surgery.
Methods A systematic review of the current literature for randomized trials, retrospective studies, and case series with 
patients undergoing hepatectomies for oesophageal and oesophagogastric junction cancer liver metastases was conducted 
up to the 31st of August 2021 using the MEDLINE (PubMed) and Cochrane Library databases.
Results A total of 661 articles were identified. After removal of duplicates, 483 articles were screened, of which 11 met 
the inclusion criteria. The available literature suggests that ECLM resection in patients with liver oligometastatic disease 
may lead to improved survival and even long-term survival in some cases. The response to concomitant chemotherapy and 
liver resection seems to be of significance. Furthermore, a long disease-free interval in metachronous disease, low number 
of liver metastases, young age, and good overall performance status have been described as potential predictive markers of 
outcome for the resection of liver metastases.
Conclusion Surgery may be offered to carefully selected patients to potentially improve survival rates compared to palliative 
treatment approaches. Studies with standardized patient selection criteria and treatment protocols are required to further 
define the role for surgery in ECLM. In this context, particular consideration should be given to neoadjuvant treatment con-
cepts including immunotherapies in stage IVB oesophageal and oesophagogastric junction cancer.
Keywords Oesophageal cancer · Liver metastases · Oesophagogastric junction cancer · Liver resection · Metastasectomy · 
Multimodal treatment
Introduction
The treatment of oesophageal cancer has markedly improved 
over the last decades. Embedded in a multimodal treatment 
concept, 5-year survival rates around 50% can be achieved 
given the absence of distant metastatic disease [1, 2]. How-
ever, patients with stage IVB oesophageal cancer are gen-
erally treated in a palliative intention with chemotherapy 
or best supportive care and have a poor median survival 
between 4 and 8 months [3].
Hepatic metastases remain one of the most common sites 
of distant dissemination in oesophageal cancer (EC) with 
an incidence of 35–40% at the time of diagnosis. It also 
represents the first site of recurrence in 6–25% of cases after 
oesophagectomy with curative intent [4, 5].
Over the last decades, liver resections for metastatic can-
cer have become a standard treatment for defined tumour 
entities, especially in patients with colorectal cancer (CRC) 
and neuroendocrine tumours. Overall perioperative mortal-
ity rates between 1 and 5% have been reported, although a 
high dependency on case load per centre and the average 
extent of liver surgeries (minor resections up to extended 
hepatectomies) have to be taken into consideration when 
comparing these studies [6–8]. However, 5-year overall 
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survival (OS) rates over 50% was achievable in patients who 
underwent liver resections for CRC liver metastases [9, 10].
The role for liver resections in liver oligometastatic EC 
remains controversial and the available literature is scarce. 
Some studies reported improved survival rates in patients, 
who underwent oesophageal cancer liver metastases 
(ECLM) resection, if compared to palliative treatment alone 
[11–13]. Other studies reported little or no survival benefit, 
which raises the question what criteria might help to stratify 
patients that may benefit from a surgical approach [14, 15]. 
This article provides an overview of the available literature 
and the role for surgery in patients with ECLM.
Methods
A systematic literature search was conducted using the 
MEDLINE (PubMed) and Cochrane Library databases. 
Studies with cancer patients undergoing surgery for oesoph-
ageal or gastroesophageal cancer liver metastases were 
included, if an appropriate follow-up with information on 
survival following surgery was available. The search strategy 
included combinations of the following keywords: ‘esopha-
geal cancer’, ‘esophagogastric junction cancer’, ‘gastroe-
sophageal adenocarcinoma’, ‘liver resection’, ‘hepatectomy’, 
and ‘metastasectomy’.
Only original articles in English were considered for this 
systematic review. Case reports and case series with less 
than 4 patients were excluded. Studies with patients, who 
underwent liver resections for multiple tumour entities, were 
excluded, if there was no sufficient subgroup data available 
on patients with oesophageal or oesophagogastric junction 
cancer liver metastases.
The search was carried out until the 31st of August 2021 
and identified 653 articles. Further 8 articles were added 
from the references of other systematic reviews. After 
removal of duplicates, 483 articles were screened. Following 
this, 407 articles were excluded as abstracts and titles did not 
meet the inclusion criteria. The remaining 76 articles were 
reviewed by full text. Finally, 11 articles met the inclusion 
criteria and were included in the systematic review.
Resection for non‑colorectal/
non‑neuroendocrine liver metastases
The surgical treatment for colorectal and neuroendocrine 
liver metastases has become the standard of care, given 
that a complete curative resection can be achieved [16, 
17]. However, liver metastasis resection for non-colo-
rectal/non-neuroendocrine primary tumours remains a 
controversial issue and no clear international level 1 rec-
ommendations are available, with many basing practice 
on case series and anecdotal evidence. Some studies 
demonstrate improved short-term survival rates and even 
long-term survival in patients, who underwent resec-
tions for non-colorectal/non-neuroendocrine liver metas-
tases (NCNNLM) [18–21]. Following the resection of 
NCNNLM, 5-year overall survival rates between 30 and 
61% have been reported [18, 20, 21]. However, direct cor-
relations on reported survival rates cannot be drawn due 
to heterogeneity of primary tumours and the percentage 
of patients with ECLM within these studies is generally 
very low to zero. It has been demonstrated that the survival 
advantage depends on the primary site with patients under-
going resection for genitourinary liver metastases benefit-
ting the most in terms of overall survival [22]. Patients 
with liver metastases from gastroesophageal primaries 
were found to have less favourable results with a median 
survival between 16 and 26 months [18, 22, 23].
However, a recent study from 2018 analysed 1792 
patients with metastatic adenocarcinoma of the stomach, the 
oesophagogastric junction, and the distal oesophagus [24]. 
Of these, 92 patients (5%) underwent metastasectomy with 
the most common metastatic sites being peritoneal (29%), 
hepatic (24%), and distant lymph nodes (11%). The study 
included two patients with oesophageal and ten patients with 
oesophagogastric junction primaries. Patients, who under-
went surgery for metastatic disease, had higher survival rates 
compared to conservatively treated patients. The median OS 
after metastasectomy was 16.7 months with a 3-year OS 
after surgery of 30.6%, which is beyond the results that can 
be achieved with palliative chemotherapy alone [3].
Similar results were provided by Schmidt et al., who 
reported a median survival of 21.3 months with a 3-year 
OS of 29.5% and a 5-year OS of 21.9% in 112 patients with 
metastatic gastric or oesophagogastric junction cancer that 
underwent surgical resection [25]. Badgwell et al. demon-
strated a 5-year OS of 25% in 82 patients after resection 
of oesophagogastric cancer metastases [26]. The subgroup 
of patients, in whom solid organ metastases were resected, 
had an even higher 5-year OS of 34%. Another study by 
Andreou et al. reported a median survival of 18 months in 
47 patients undergoing hepatectomy for oesophagogastric 
cancer metastases with 3- and 5-year OS rates of 37% and 
24%, respectively [27].
Taken together, the resection of NCNNLM from gas-
troesophageal primaries may offer improved survival rates, 
although clear selection criteria for patients benefitting from 
a surgical approach have not yet been defined. However, the 
above-mentioned studies with metastatic gastroesophageal 
cancers may not be transferable to EC patients as they mostly 
consisted of patients with gastric and oesophagogastric junc-
tion adenocarcinomas and, if any, a negligible number of 
distal oesophageal AC. Similarly, there were no patients with 
oesophageal SCC in these studies (Table 1).
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Liver resection for oesophageal cancer liver 
metastases
The literature on patients that underwent surgery for 
ECLM is scant. The few available studies are of retrospec-
tive design with low patient numbers and are significantly 
biased by patient selection (Table 2). However, there is 
data that may encourage a more aggressive multimodal 
treatment approach including surgery in selected patients 
with stage IVB EC [28–31].
The authors of a retrospective study from 2016 identi-
fied 96 patients with stage IVB EC that were treated with 
chemotherapy followed by concurrent chemoradiotherapy 
(CRT) [32]. A subset of 14 patients also received surgery 
(11 patients for non-regional lymph node metastases, 3 
patients for distant organ metastases). The median OS of 
all patients was 21.0 months. The median OS in the sub-
group of patients that received surgery was not reached 
and a corresponding 5-year OS rate of 50.5% was reported 
vs 20 months and a 5-year OS rate of 11.7% for those 
without surgery. However, there was a strong patient selec-
tion bias as patients in the group receiving surgery tended 
to be younger and were less likely to have distant organ 
metastases.
In 2015, Huddy et  al. published a case series that 
included four patients that underwent liver resection for 
metachronous liver metastases following a curatively 
intended oesophagectomy [12]. Two out of the four 
patients were still alive and without evidence for recurrent 
disease 22 and 92 months after liver resection. Adam et al. 
found a median OS of 16 months and a 3-year survival 
rate of 32% in patients, who underwent resection for syn-
chronous and metachronous ECLM [18]. Similar survival 
rates were reported by Liu and colleagues, who published 
a retrospective study with 69 consecutive patients with 
metachronous, solitary ECLM [33]. A subgroup of 26 
patients underwent liver resection, whereas the remain-
ing 43 patients were treated conservatively with chemo-
therapy and additional local therapies including radiofre-
quency ablation (n = 16), high intensity focused ultrasound 
(n = 12), or microwave ablation (n = 15). Patients in the 
surgical group had significantly higher 1- and 2-year sur-
vival rates compared to the non-surgically treated patients 
(50.8% and 21.2% vs. 31% and 7.1%, p = 0.027 and < 0.05, 
respectively).
A recently published study by Seesing et al. included 
34 patients, in whom a resection of gastroesophageal can-
cer metastases was performed [5]. Of these patients, 19 
received a resection of hepatic metastases and 15 a resec-
tion of pulmonary metastases. A subgroup analysis of the 
patients with ECLM (n = 11) revealed a median OS of 
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27%, respectively. The survival after pulmonary metasta-
sectomy (n = 11) was even higher with 1-, 3-, and 5-year 
OS of 82%, 64%, and 64%, respectively. Similar results 
were provided by Van Deale et al. in a retrospective study 
consisting of 12 patients with EC and synchronous liver 
(n = 6) or lymph node metastases (n = 5) as well as one 
patient with liver and lymph node metastases [13]. Ten 
patients underwent an Ivor-Lewis oesophagectomy with a 
two-field lymphadenectomy. The metastatic liver lesions 
were treated synchronously via wedge resection (n = 4), 
radiofrequency ablation (n = 1), or microwave ablation 
(n = 1); the five patients with distant lymph node metasta-
ses underwent surgical resection. After a median follow-up 
of 22 months, 50% of the surgically resected patients were 
still alive with 33% being free of disease recurrence.
Ichida et  al. conducted a retrospective study that 
included 315 patients, who had undergone curatively 
intended oesophagectomies [11]. During a median follow-
up period of 47 months, 138 patients (47%) developed 
disease recurrence. Five out of 26 patients with hepatic 
recurrences were treated with hepatic metastasectomy. A 
trend towards an improved survival in the group receiv-
ing surgery vs. no surgery could be observed (median OS 
13 vs. 5 months). However, the non-surgically treated 
patients had either multinodular hepatic recurrence and/
or additional extrahepatic recurrence or a poor general per-
formance status, which makes a direct comparison with 
the surgically treated patients difficult. Nonetheless, there 
was one patient after hepatic resection, who was still alive 
and without evidence of recurrent disease 70 months after 
recurrence detection.
A recently published article reviewed studies and case 
reports with patients suffering from liver oligometastatic EC 
[4]. The authors concluded that surgery seems to be the treat-
ment of choice for resectable ECLM, especially for patients 
with 3 or less lesions. However, the review included only ret-
rospective studies and small case reports/case series. Due to 
their significant heterogeneity, patient selection bias, small 
patient numbers, and a lack of defined treatment protocols, 
these studies may not support such definite conclusions.
Nevertheless, the survival rates provided by Seesing and 
van Daele following ECLM resection are very encouraging 
[5, 13]. Therefore, the authors suggest to discuss the option 
of ECLM resection in MDT meetings, especially for suitable 
patients with liver oligometastatic disease.
Factors associated with an improved 
survival after resection of ECLM
Preoperative chemotherapy
As most of the studies with patients undergoing ECLM 
resection included only small patient numbers, the role of 
preoperative (palliative/neoadjuvant) chemotherapy has not 
been assessed appropriately. However, there is some evi-
dence that preoperative chemotherapy may positively impact 
on survival rates, as a response to chemotherapy or a lack of 
progression was either a positive prognostic marker in surgi-
cally treated metastatic gastroesophageal cancer patients or 
it was used as selection criterion for a surgical approach in 
ECLM in the first place [12, 13, 24, 25, 27]. However, this 
Table 2  Studies with patients undergoing liver resection for ECLM
ECLM oesophageal cancer liver metastases, CTx chemotherapy, AC adenocarcinoma, SCC squamous cell carcinoma, syn synchronous, meta 
metachronous, n.s. not stated. Survival times are calculated from the date of metastatic surgery unless otherwise stated
* Calculated from the date of ECLM diagnosis
** Out of the total of 12 patients, 7 patients underwent hepatectomy for liver metastases and 5 patients underwent resection of distant lymph node 
metastases
















3-y OS (%) 5-y OS (%)
Adam 2006 20 n.s n.s n.s n.s 16 32 n.s
Huddy 2015 4 3 (75) AC
1 (25) SCC
meta 4 (100) n.s 10–92 n.s n.s
Ichida 2013 5 4 (80) SCC
1 (20) n.s
meta 0 n.s 13 (2–70)* n.s n.s
Liu 2018 26 26 (100) SCC meta n.s 8 (1.0–38.0) n.s 21.2* n.s
Seesing 2019 11 9 (81.8) AC
1 (9.1) SCC
1 (9.1) n.s
meta > syn  < 4 (< 21.1) 54 52 55 27
Van Daele 
2017
7 (12**) 9 (75) AC
3 (25) SCC
syn 7 (100) 22 (8–50) 22 (8–51)* n.s n.s
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could be more accurate for patients with synchronous ECLM 
that were often treated with simultaneous resection of the 
primary tumour and the metastasis(-es). Seesing and col-
leagues demonstrated superior survival rates in patients with 
predominantly metachronous liver metastases that under-
went surgery to a large extent without prior chemotherapy 
[5]. On the contrary, all five patients in the study by Ichida 
et al. underwent surgery for metachronous ECLM without 
prior chemotherapy and had a relatively poor median sur-
vival of 13 months postmetastasectomy [11].
Wang et al. investigated the impact of a multimodal treat-
ment approach in stage IVB EC that included surgery of the 
primary tumour and the metastatic lesion in selected cases 
[32]. All patients (n = 96) received palliative chemotherapy 
followed by concurrent CRT. Of these, 14 patients also 
underwent surgery as mentioned above. In a multivariate 
analysis, the radiographic response of the primary tumour 
to induction chemotherapy (complete vs incomplete) was 
associated with an improved OS. A radiologic complete 
response was defined as a lack of residual SUV after treat-
ment assessed via PET/CT. When concurrent CRT response 
variables were not included in the multivariate analysis, the 
receipt of surgery was a significant independent predictor of 
improved OS and disease-free survival (DFS). Intriguingly, 
the radiographic response of the primary tumour to induc-
tion chemotherapy or concurrent CRT appeared to be of 
more significance than the response of the metastatic lesions.
Another study from 2015 included 112 patients with 
metastatic gastric or oesophagogastric junction adeno-
carcinomas that underwent surgical resection [25]. In the 
subgroup of patients that received neoadjuvant treatment 
(n = 72), the clinical responders (defined by a decrease of 
the maximal transversal primary tumour diameter of > 50% 
measured on CT and a decrease of the endoluminal tumour 
size of > 75% on endoscopic findings) had a significantly 
prolonged median survival compared to the non-responders 
(77.3 months vs 23.5 months; p < 0.001). Moreover, the 
group that did not receive preoperative chemotherapy had 
a significantly reduced median survival compared to the 
group, in which a preoperative chemotherapy was admin-
istered (11.0 months vs 31.1 months, p < 0.001). Therefore, 
the authors of the study concluded that a primary resection 
is not appropriate for patients with metastatic gastroesopha-
geal cancer.
Similar findings were provided by Andreou et al., who 
published a retrospective study with 47 gastroesophageal 
cancer patients, in whom hepatic resections for mainly syn-
chronous liver metastases were performed [27]. Of these, 32 
patients underwent a simultaneous resection of the primary 
tumour and hepatic metastases. In the multivariate analy-
sis, not undergoing preoperative chemotherapy was signifi-
cantly associated with poor survival (5-year OS: 9% vs 45%, 
p = 0.005). In the subset of patients receiving preoperative 
chemotherapy (n = 20), the patients responding to the pre-
operative treatment or with stable disease on radiographic 
imaging (n = 13) had a significantly improved OS compared 
to those with progressive disease (n = 7) (5-year OS rate: 
70% vs 0%, p = 0.045).
As opposed to the two studies mentioned above, a 
Dutch study reported superior survival rates in 19 patients 
with hepatic metastases from gastroesophageal primaries 
(8 × gastric primary, 11 × oesophageal primary), of which 
only 4 received neoadjuvant treatment prior to metastasec-
tomy [5]. After resection of the predominantly metachro-
nous liver metastases (17 × deriving from AC, 2 × from 
SCC), the median OS was 28 months and the 3- and 5-year 
survival rates were 41% and 31%, respectively. These con-
trary findings can lead to the conclusion that synchronous 
and metachronous liver metastases from gastroesophageal 
primaries have a differing underlying tumour biology and 
may require different patient selection criteria and treatment 
approaches.
However, the timing after receipt of preoperative (pal-
liative) chemotherapy may play a pivotal role that needs to 
be taken into consideration when patients with ECLM are 
evaluated for surgery as the group around Carmona-Bayonas 
found that a longer duration of chemotherapy prior to sur-
gery increases mortality (HR 1.04, p = 0.009) [24].
Patient and tumour‑related factors
In a study from 2014 on 23 patients with pulmonary, pre-
dominantly metachronous metastases from oesophageal 
SCC, a short disease-free interval (DFI) < 12 months was 
associated with poor survival (p = 0.02) [34]. These results 
were in keeping with previous study results from 2008 [35]. 
Liu et al. could show similar results for patients with ECLM 
[33]. In this study, the outcomes of patients that underwent 
surgery for metachronous ECLM were compared with a 
group of non-surgically treated patients. A DFI > 12 months 
was associated with a significantly improved survival rate 
in both groups (p [both] < 0.05). Seesing and colleagues 
reported superior survival rates in 11 patients following the 
resection of mainly metachronous ECLM [5]. The patients 
included in the study had a DFI between 11 and 27 months, 
which supports the assumption that patients with a longer 
DFI may benefit from surgery. Conversely, Ichida et al. 
reported a median DFI of 6 months (0–14) in patients that 
underwent ECLM resection [11]. The study could not dem-
onstrate a survival benefit of the surgically treated patients 
compared to a group that was treated conservatively (median 
survival 13 vs 5 months, p = 0.06).
The differentiation of the tumour may also have prognos-
tic relevance when evaluating patients for ECLM resection. 
Poorly differentiated primary tumours have been mentioned 
as negative prognostic markers in metastatic EC [34].
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Moreover, a complete resection of all tumour manifesta-
tions with overall clear resection margins (R0-resection) 
was reported to have a significant impact on survival rates in 
limited metastatic gastroesophageal cancers [25, 27, 32, 36]. 
Schmidt et al. demonstrated that complete resection of the pri-
mary tumour and the metastases in these patients lead to a sig-
nificantly improved median survival of 29.5 months compared 
to patients with incomplete resection (R1/2) (p = 0.003) [25]. 
Andreou et al. could show that an R1-resection in patients that 
underwent hepatectomy for oesophagogastric cancer was asso-
ciated with a poor OS [27]. Chao and colleagues revealed that 
scheduled surgery following CRT in patients with oesophageal 
SCC and distant nodal metastases (nodal M1a/b disease) leads 
to a survival benefit only in patients, in whom an R0-resection 
had been achieved (median OS 45 months vs 9.5 months after 
incomplete resection and 10.5 months in patients receiving 
definitive CRT, p = 0.0013) [36]. Analogously, the two studies 
with the longest OS following ECLM resection had high rates 
of R0-resections of about 90% [5, 13].
In the available literature, only patients with a low 
number of liver metastases/metastatic deposits underwent 
resection of ECLM. In the two studies with the longest OS 
after resection of ECLM, 77% (n = 20) of the patients had 
solitary liver metastases, 15% (n = 4) had two liver lesions, 
and only one patient was treated for 3 liver metastases [5, 
13]. Although significantly affected by selection bias, these 
results may indicate that patients with a low metastatic 
burden could potentially benefit from a surgical approach. 
Therefore, a thorough preoperative radiographic imaging 
including CT, MRI, PET-CT, and (endoscopic) ultrasound/
CEUS is of utmost importance [37].
Furthermore, the patients’ age and performance status 
need to be taken into account like in other areas where 
major surgery is being considered as young and relatively fit 
patients with stage IVB EC seem to benefit from an aggres-
sive multimodal therapy including surgery [32].
The response to chemotherapy seems to be a significant 
factor in patients undergoing ECLM resection (this may 
also hold true for the response to targeted therapies/immu-
notherapies, although studies referring to this are not avail-
able as of yet). Therefore, in patients with a good response 
to chemotherapy and/or other potentially favourable factors 
such as a long disease-free interval in metachronous disease, 
low number of liver metastases, young age, and good overall 
performance status, ECLM resection should be considered, 
if an R0 resection status is achievable.
Discussion
Liver resections for liver oligometastatic EC remain a con-
troversial issue as the available data is scarce and often 
of poor quality. Nevertheless, the few available studies 
demonstrated a survival benefit in patients that underwent 
liver resections in stage IVB EC, if compared to palliative 
chemotherapy only [3, 13]. In highly selected patients, 
5-year survival rates up to 27% have been reported [5]. Even 
a chance for long-term survival seems possible [11, 12]. 
However, the main limitation of all the available studies on 
ECLM resection is that they are significantly biased. The 
lack of consistent patient selection criteria and treatment 
protocols disallow any definite conclusions as to whether 
ECLM resection should be part of the common armamen-
tarium in the treatment of metastatic EC. Nevertheless, 
although being of limited validity, the available data speaks 
against the proposition that there is no role for surgery in 
metastatic EC. Patients with liver oligometastatic EC that 
responded well to palliative chemotherapy/CRT or with a 
long DFI > 12 months after primary surgery may benefit 
from ECLM resection, given a good performance status and 
the chance of a complete resection of all tumour manifesta-
tions [5, 27, 32, 33]. At the same time, the potential intraop-
erative and/or postoperative complications of liver resections 
need to be taken into account. In spite of the improvements 
in surgical techniques and perioperative management, the 
potential complications accompanying liver resections may 
further shorten the already limited lifetime of patients with 
metastatic EC, especially when extended hepatectomies are 
required in order to achieve an R0-resection status [6]. In 
patients with liver metastases from gastric and oesophageal 
cancer, posthepatectomy complications were found to be an 
independent predictor of poor overall survival [27]. In some 
cases, the required extent of liver resection is being under-
estimated in the preoperative radiographic imaging [26]. 
In accordance with the principle ‘primum non nocere’, a 
relevant number of planned ECLM resections may have to 
be abandoned after surgical exploration if the resection of 
ECLM would require more extended hepatectomies. Alter-
natively, surgical and interventional approaches such as radi-
ofrequency ablation or microwave ablation can be combined 
in order to avoid major liver resections [4]. In this context, 
high-quality imaging (i.e. MRI with liver-specific contrast 
and diffusion weighting) is of vital concernment in order to 
develop a thorough multimodal treatment plan in patients 
with ECLM [37, 38].
A tool similar to the one developed by Blank and col-
leagues for patients with metastatic gastric and oesophago-
gastric junction cancer may help to identify patients that 
could benefit from ECLM resection [39]. The score defines 
a low-risk group according to tumour differentiation, histo-
pathological response to prior chemotherapy, and (antici-
pated) resection status (complete vs. incomplete resection). 
Patients in the low-risk group (n = 22) had a significantly 
improved median survival of 35.3 months and a 3-year OS 
of 47.6% compared to 12.0 months and a 3-year OS of 14.2% 
in the high-risk group (n = 126).
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There is further evidence that may favour surgery in patients 
with limited metastatic disease from oesophageal AC. The 
AIO-FLOT 3 trial evaluated the outcomes in patients with 
limited metastatic gastric or EGJ cancer, who received chem-
otherapy followed by surgical resection [40]. Out of the 67 
patients with limited metastatic disease, 36 (60%) proceeded 
to surgery. The median OS was 31.3 months for patients who 
underwent surgery compared to 15.9 months for patients that 
received a non-surgical treatment. A limitation of these results 
is the lack of randomization for the patients with limited meta-
static disease in the group receiving surgery vs chemotherapy 
only. To address this issue, the RENAISSANCE (AIO-FLOT 
5) Trial as a prospective, multicentre phase III trial is currently 
recruiting patients with the aim to compare these two groups 
in a randomized manner [41]. Whether these findings can be 
adopted for ECLM will require further prospective studies, 
although a comparable outcome for distal oesophageal adeno-
carcinoma seems to suggest itself because of its molecular 
similarity with gastric cancer [42]. However, a transferability 
of the results to liver metastases deriving from oesophageal 
SCC is problematic as oesophageal SCCs seem to have a dif-
ferent tumour biology and differences in lymphatic spread 
compared to adenocarcinomas [42–44]. Therefore, ECLM 
from SCC and AC should be separately evaluated.
Conclusion
The available literature is limited and does not facilitate defi-
nite conclusions as to whether the resection of ECLM should 
be standard practice as part of the multimodal treatment con-
cept in metastatic oesophageal cancer. Notwithstanding this, 
there is enough evidence to justify further studies to identify 
those select patients with a favourable tumour biology who 
may benefit from such treatment approaches, especially in the 
light of emerging immunotherapies.
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